reason report
posit fa data set sight cardin rais pt
bottom line investor like welcom moxi part data
friedreich ataxia fa intra-day merit
fa also posit tailwind upcom cardin alport
syndrom data also expect statist signific benefit
shown modifi fa rate scale mfar approv endpoint
fda along improv pt physician assess
daili activ suggest omaveloxolon omav could becom first
fda-approv therapi fa detail data disclosur futur medic
meet public interest convinc
robust improv seen multipl concord measur
increas po result increas pt
reiter op
posit omav fa new pt follow initi
take link increas omav probabl success po
vs previous updat opex reflect
global commerci build continu project peak ww sale
fa alon although intrigu potenti
omav address neurodegen diseas road
valuat directli account potenti scarciti valu
biotech platform could broad util attract
acquir although remain optimist upcom cardin
data may indic real possibl
mfar secondari endpoint support omav therapeut
benefit fa detail present forthcom futur medic
meet similar baselin diseas sever part point
mfar treatment cohort demonstr stat sig improv
point vs point placebo delta point
although placebo pt also improv first week curv
separ dramat thereaft treat cohort continu
benefit period anticip granular detail
baselin characterist subdomain breakdown mfar
present futur medic meet public meanwhil
secondari endpoint -- pt global impress chang pgic
activ daili live adl -- also correl posit trend
seen mfar cite variabl measur management note
improv pgic primari analysi
random adl primari analysi whether
secondari endpoint measur make final label remain
determin although believ patient demand like robust
continu next page
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep present
pleas refer page import disclosur price chart analyst certif
omav show favor safeti profil advers event ae
gener mild-to-moder intens omav arm show
higher incid headach nausea elev alt alanin
aminotransferas ast aspart aminotransferas fatigu
abdomin pain importantli remind investor alt/ast
increas known pharmacolog effect/potenti biomark
omav measur liver function bilirubin actual show
improv lastli although small number higher rate
discontinu omav arm vs pbo
elig pt elect particip moxi part extens
studi suggest high satisfact favor profil among pt
incred prescient time op right link show
real moxi manag given proxim reacquir
right moxi data investor wonder knew
us think decis base
steadfast convict biolog prescient time
pro move experienc recent bolster manag
team upcom regulatori discuss notwithstand management
commit engag fa pt commun rais awar
build commerci infrastructur ex-u encouragingli
on-going fa registri fara alreadi identifi pt us
could acceler initi uptak omav receiv regulatori approv
better risk-reward profil may mean attract
entri point investor prior moxi data
believ investor remain sidelin reluct risk
capit binari outcom close year-end link
posit moxi data provid floor valu notwithstand
higher altitud anticip capit inflow reason
improv sentiment activ platform includ bardoxolon
bard cardin de-risk moxi
matur invest profil better risk-reward post-moxi
although differ indic believ moxi partial
valid biolog therapeut target may broader
reach beyond fa particularli true alport syndrom sever
form chronic kidney disease/ckd wherein bardoxolon
alreadi demonstr improv estim glomerular filtrat
egfr measur kidney function investor see cardin
de-risk base cardin data believ investor
optim cautious optimist head data thirdli
stock today believ fa establish floor
valu wherea pre-moxi downsid risk
cash investor may encount less dramat downsid risk
believ reason could translat investor
comfort own junctur prospect regulatori
approv bard omav could appeal differ cohort
investor interest commerci stage compani
rate reata share outperform clinical-stag biopharmaceut compani
dedic develop commerci novel therapi aim rectifi
life-threaten metabol diseas current approv treatment
compani two lead compound bardoxolon methyl bard omaveloxolon omav
small molecul activ import protein involv maintain mitochondri
function reduc oxid stress resolv inflamm via suppress nf-kb
enthusiast metabol approach therapi fundament natur afford
potenti pursu extens therapeut portfolio current cover eight area
diseas enrol patient proof-of-concept studi potenti pivot
across sever target rare diseas believ potenti gener posit
data therebi advanc compani develop profil de-risk invest
charact stock encourag safeti learn extens previou
develop work bard may enabl strong therapeut profil achiev
multipl larg market opportun ripe innov bardoxolon studi
catalyst trial treatment connect tissu disease-associ pulmonari arteri
hypertens ctd-pah previous demonstr abil improv walk
distanc baselin key function measur diseas progress patient
popul suggest potenti superior current approv therapi vasodilatori
ctd-pah account pah patient repres opportun gain meaning
market share crowd pah market addit catalyst view compani
rare renal franchis compos alport syndrom autosom domin polycyst kidney
diseas adpkd low-risk/high-reward strategi bardoxolon view consist
benefit seen part phase moxi trial omaveloxolon friedreich ataxia
fa program promis indic omav potenti rectifi function neurolog
deterior symptomat fa beyond three lead program longer term upsid could come
progress pipelin focus mitochondri myopathi pulmonari hypertension-ild
melanoma rare kidney diseas orphan neurolog indic
rate share outperform pt leverag proprietari
target therapi bard omav develop novel therapeut patient rare
life-threaten diseas caus dysregul metabol mitochondri function
reta program seek either improv upon current standard care ctd-pah
becom first-to-market therapi diseas approv therapi exist alport
syndrom friedreich ataxia fa mitochondri myopathi conserv project
probabl success po bard ctd-pah due advanc follow
rel small phase residu uncertainti surround mechan
action appropri patient popul howev believ catalyst trial
highli power alport syndrom ascrib po bard base highli
encourag cardin data extens clinic histori increas estim glomerular
filtrat rate egfr singl endpoint approv ascrib po omav fa
follow posit part moxi data could registr base posit ph
phoenix data includ model assign po well
po adkpkd po lgan bardoxolon model assign credit
program potenti revenu gener collabor reta pipelin
multipl innov product routin seen clinic stage biotechnolog compani
result develop regulatori market reimburs uncertainti believ
share best valu via dcf analysi use discount rate termin
growth rate yield pt
pre-commerci stage compani risk valuat includ clinic trial outcom delay
clinic develop regulatori risk prior approv reimburs risk post-approv
also sinc bardoxolon omaveloxolon first-in-class therapi unforeseen complic
risk may emerg financi perspect clinic develop requir signific
invest could necessit dilut financ road
 except ep
total incom expens
equival
chang cash
receiv collabor arrang
prepaid expens current asset
accru direct research current liabil
proce long-term debt
pymnt defer disc issuanc cost
proce stock offer
payment defer offer cost
debt pay
proce sharehold promissori note
exercis option
payment capit leas
autoimmun inflammatori disord
safeti pk
